Theranautilus Secures $1.2 Mn Seed Funding to Advance Nanorobotics in Healthcare

The funding will accelerate the clinical development of nanorobotic medical devices and facilitate global market entry, starting with dental care applications.

Theranautilus, a deeptech company specializing in nanorobotic healthcare solutions, announced raising $1.2 million in a seed round led by Pi Ventures.

Golden Sparrow Ventures and angel investors, including Abhishek Goyal, CEO of Tracxn, and Lalit Keshre, CEO of Groww, also participated in the round. The funding will accelerate the clinical development of nanorobotic medical devices and facilitate global market entry, starting with dental care applications.

“The support from Pi Ventures and other investors strengthens our efforts to transform dental health using nanotechnology,” said Professor Ambarish Ghosh, Co-founder of Theranautilus. “We are excited to develop a first-of-its-kind solution that could significantly impact the healthcare landscape.”

Focus on Dental Hypersensitivity Treatment

Founded in 2020 and incubated at the Indian Institute of Science (IISc), Theranautilus focuses on addressing critical dental health challenges, including hypersensitivity, a condition affecting over two billion people worldwide. The current market for hypersensitivity solutions, estimated at $6 billion, predominantly relies on specialized toothpaste, which requires repeated use.

Theranautilus’s technology employs precision-manufactured nanorobots that deliver biocompatible materials to targeted areas within dental tissues. These materials can be triggered externally to form bio-mimetic structures, repairing damaged tissue and providing long-lasting relief in just a ten-minute procedure.

“This funding will help us advance our plans to bring our innovative solution to clinical trials and beyond. We aim to improve patient outcomes with a more effective and durable approach to dental treatments,” said Dr Debayan Dasgupta, Co-founder of Theranautilus.

While the initial focus is on dental applications, Theranautilus plans to extend its nanorobotics platform to other healthcare areas, including precision theranostics for cancer therapy.

The company has secured international patents for its technology and aims to initiate human trials for its nanorobotic device in 2025.

“Our vision is to redefine how targeted treatments are delivered, starting with dentistry but eventually addressing broader medical challenges,” said Dr Peddi Shanmukh Srinivas, Co-founder.